Endostatin inhibits the proliferation and migration of B16 cells by inducing macrophage polarity to M1‑type

Guo,Hua; Zhou,Longyuan; Guo,Jun; Huang,Xueqin; Gu,Junlian

doi:10.3892/mmr.2021.12481

Endostatin inhibits the proliferation and migration of B16 cells by inducing macrophage polarity to M1‑type

Authors:
- Hua Guo
- Longyuan Zhou
- Jun Guo
- Xueqin Huang
- Junlian Gu
View Affiliations

Affiliations: Department of Pathology and Pathogen Biology, Ningbo University School of Medical, Ningbo, Zhejiang 315211, P.R. China, Department of Anesthesiology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang 315211, P.R. China, Department of Pathology, Sanquan College of Xinxiang Medical University, Xinxiang, Henan 453000, P.R. China, School of Nursing and Rehabilitation, Cheeloo College of Medicine, Shangdong University, Jinan, Shandong 250012, P.R. China
Published online on: October 11, 2021 https://doi.org/10.3892/mmr.2021.12481
Article Number: 841

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant melanoma is a common skin tumor that easily metastasizes and has a poor prognosis. Endostatin is an endogenous vascular endothelial inhibitor that mainly suppresses tumor growth by inhibiting the proliferation of vascular endothelial cells and by reducing the formation of tumor microvessels, however the immunological function of endostatin remains unclear. Previously, we have found that an over‑expression endostatin (pEndostatin) plasmid induced RAW264.7 cells' polarity to M1‑type macrophage. To elucidate the effect of M1‑type macrophages induced by endostatin on melanoma B16 cells, the present study transfected RAW264.7 cells with pEndostatin plasmid and co‑cultured them with B16 cells. Compared with the control group, the expression of matrix metalloproteinase (MMP)‑2, MMP‑9 and proliferating cell nuclear antigen in B16 cells was inhibited by M1‑type macrophages, but cleaved Caspase‑3 and cleaved Caspase‑8 were significantly upregulated and the ratio of Bax/Bcl‑2 was increased. These results indicated that M1 macrophages induced by pEndostatin plasmid inhibited the proliferation and migration of B16 cells and promoted their apoptosis. These findings suggest that the inhibitory effect of endostatin on melanoma is not limited to directly inhibiting tumor microvessel formation, but it may also be related to regulating changes in macrophage polarity.

View Figures

View References

1	Henley SJ, Ward EM, Scott S, Ma J, Anderson RN, Firth AU, Thomas CC, Islami F, Weir HK, Lewis DR, et al: Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer. 126:2225–2249. 2020. View Article : Google Scholar
2	Uprety D, Bista A, Chennamadhavuni A, Niroula A, Jafri SIM, Smith A and Arjyal L: Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: A US population-based study. Melanoma Res. 28:56–60. 2018. View Article : Google Scholar
3	Ladányi A: Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma. Pigment Cell Melanoma Res. 28:490–500. 2015. View Article : Google Scholar
4	Yang L and Zhang Y: Tumor-associated macrophages: From basic research to clinical application. J Hematol Oncol. 10:582017. View Article : Google Scholar
5	Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A and Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25:677–686. 2004. View Article : Google Scholar
6	Fuxe J and Karlsson MC: TGF-β-induced epithelial-mesenchymal transition: A link between cancer and inflammation. Semin Cancer Biol. 22:455–461. 2012. View Article : Google Scholar
7	Walia A, Yang JF, Huang YH, Rosenblatt MI, Chang JH and Azar DT: Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications. Biochim Biophys Acta. 1850:2422–2438. 2015. View Article : Google Scholar
8	Guo H, Liu Y, Gu J, Wang Y, Liu L, Zhang P and Li Y: Endostatin inhibits the growth and migration of 4T1 mouse breast cancer cells by skewing macrophage polarity toward the M1 phenotype. Cancer Immunol Immunother. 65:677–688. 2016. View Article : Google Scholar
9	Jia H, Li Y, Zhao T, Li X, Hu J, Yin D, Guo B, Kopecko DJ, Zhao X, Zhang L, et al: Antitumor effects of Stat3-siRNA and endostatin combined therapies, delivered by attenuated Salmonella, on orthotopically implanted hepatocarcinoma. Cancer Immunol Immunother. 61:1977–1987. 2012. View Article : Google Scholar
10	Wang H, Yang L, Wang D, Zhang Q and Zhang L: Pro-tumor activities of macrophages in the progression of melanoma. Hum Vaccin Immunother. 13:1556–1562. 2017. View Article : Google Scholar
11	Umansky V and Sevko A: Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron. 6:169–177. 2013. View Article : Google Scholar
12	Ruffell B and Coussens LM: Macrophages and therapeutic resistance in cancer. Cancer Cell. 27:462–472. 2015. View Article : Google Scholar
13	Skobe M, Hamberg LM, Hawighorst T, Schirner M, Wolf GL, Alitalo K and Detmar M: Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol. 159:893–903. 2001. View Article : Google Scholar
14	Wang H and Zhang L, Yang L, Liu C, Zhang Q and Zhang L: Targeting macrophage anti-tumor activity to suppress melanoma progression. Oncotarget. 8:18486–18496. 2017. View Article : Google Scholar
15	Bardi GT, Smith MA and Hood JL: Melanoma exosomes promote mixed M1 and M2 macrophage polarization. Cytokine. 105:63–72. 2018. View Article : Google Scholar
16	Vodovotz Y, Bogdan C, Paik J, Xie QW and Nathan C: Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor beta. J Exp Med. 178:605–613. 1993. View Article : Google Scholar
17	Berking C, Takemoto R, Schaider H, Showe L, Satyamoorthy K, Robbins P and Herlyn M: Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling. Cancer Res. 61:8306–8316. 2001.
18	Chen P, Huang Y, Bong R, Ding Y, Song N, Wang X, Song X and Luo Y: Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in a paracrine and autocrine manner. Clin Cancer Res. 17:7230–7239. 2011. View Article : Google Scholar
19	Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, et al: Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 24:5552–5560. 2005. View Article : Google Scholar
20	Murdoch C, Muthana M, Coffelt SB and Lewis CE: The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 8:618–631. 2008. View Article : Google Scholar
21	O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR and Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell. 88:277–285. 1997. View Article : Google Scholar
22	Li K, Shi M and Qin S: Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment. Oncol Ther. 6:21–43. 2018. View Article : Google Scholar
23	Xiao L, Yang S, Hao J, Yuan X, Luo W, Jiang L, Hu Y, Fu Z, Zhang Y and Zou C: Endostar attenuates melanoma tumor growth via its interruption of b-FGF mediated angiogenesis. Cancer Lett. 359:148–154. 2015. View Article : Google Scholar
24	Zheng AW, Jia DD, Xia LM, Jin G, Wu H and Li T: Impact of carboplatin plus paclitaxel combined with endostar against A375 melanoma cells: An in vitro and in vivo analysis. Biomed Pharmacother. 83:1321–1326. 2016. View Article : Google Scholar
25	Cui C, Mao L, Chi Z, Si L, Sheng X, Kong Y, Li S, Lian B, Gu K, Tao M, et al: A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma. Mol Ther. 21:1456–1463. 2013. View Article : Google Scholar
26	Cui C, Si L, Chi Z, Sheng X and Guo J: Preliminary results of a phase II trial with continuous intravenous infusion of rh-endostatin in combination with dacarbazine as the first-line therapy for metastatic acral melanoma. Anticancer Res. 35:4350–4351. 2015.
27	Yang L, Xu Y, Luo P, Chen S, Zhu H and Wang C: Baseline platelet counts and derived inflammatory biomarkers: Prognostic relevance in metastatic melanoma patients receiving Endostar plus dacarbazine and cisplatin. Cancer Manag Res. 11:3681–3690. 2019. View Article : Google Scholar
28	Nyakas M, Aamdal E, Jacobsen KD, Guren TK, Aamdal S, Hagene KT, Brunsvig P, Yndestad A, Halvorsen B, Tasken KA, et al: Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma. Clin Exp Immunol. 197:74–82. 2019. View Article : Google Scholar
29	Liu X, Nie W, Xie Q, Chen G, Li X, Jia Y, Yin B, Qu X, Li Y and Liang J: Endostatin reverses immunosuppression of the tumor microenvironment in lung carcinoma. Oncol Lett. 15:1874–1880. 2018.
30	Liang J, Liu X, Xie Q, Chen G, Li X, Jia Y, Yin B, Qu X and Li Y: Endostatin enhances antitumor effect of tumor antigen-pulsed dendritic cell therapy in mouse xenograft model of lung carcinoma. Chin J Cancer Res. 28:452–460. 2016. View Article : Google Scholar
31	Wang X, Zhan RY, Wang YY, Yan XI, Cao D, Li Y, Wang YQ and Luo F: Endostatin improves cancer-associated systemic syndrome in a lung cancer model. Oncol Lett. 9:2023–2030. 2015. View Article : Google Scholar